Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-450 (zunsemetinib) plus methotrexate in active rheumatoid arthritis with inadequate response to methotrexate
2021-002860-31Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing zunsemetinib plus methotrexate with placebo plus methotrexate (2 arms). Primary endpoint: Proportion of patients achieving ACR20. Started Feb 2022; status: completed.
02
Drugs
zunsemetinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-002860-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002860-31.